NRC Health (NRC, ≈$400M cap) measures patient experience for US health systems. It trades at 2.9x revenue while every public pure-play peer in healthcare experience analytics has been taken private at 7-8x over the past four years. A four-week sequence of SEC filings — Schedule 13D/A March 27, Form 8-K April 20 — documents what looks like founder exit grooming. Earnings April 28 is the near-term binary.

What the filings say

Schedule 13D/A Amendment No. 3, filed 2026-03-27. Founder/Chairman Michael Hays placed 582,688 shares in irrevocable family trusts, ceasing beneficial ownership above the 5% threshold. Beans trust complex holds 46.5% aggregate. Item 6 discloses 4,833 Hays options at $39.54 strike that "vest upon the Issuer achieving a minimum total recurring contract value of $170 million as of December 31, 2026." Management has tied founder comp to the TRCV hurdle.

Form 8-K, filed 2026-04-20 (event April 15). Items 5.02 and 5.03. Board declassified from three-class staggered to annual elections at the June 23 Annual Meeting. Proxy access adopted at 3% threshold. Legal rename to "NRC Health." Chair role formalized. CFO Shane Harrison's September 2025 RSU award (172,000 shares) amended to carry voting rights and dividends on unvested shares. Separately: Harrison bought 8,000 shares on February 17 at $12.27 (Form 4 code P, $98K); stock now +48% since that purchase.

FY2025 operating results. Revenue $137.4M (-3.9%), GAAP NI $11.6M (-53%), SG&A +22%, interest expense +84%. Buybacks $20.7M debt-funded; total equity $14M, notes payable $79M. TRCV $152M+ as of March 4 — all-time high, +13% YoY, five sequential quarters of sequential growth.

What the market thinks

Stock +85% 1Y but IV at the 31st percentile, volume 0.5x three-month average, 15% short interest. Options not pricing April 28 as a binary. Takeout optionality implied at ≈15-16% probability (derived: (current price - $13 organic base) / ($45 peer-multiple takeout - $13) ≈ 0.16). Two to three analysts cover the name.

Our probability of strategic process announced by Dec 31, 2027: 45%. Edge ≈30 percentage points on that specific binary.

Why the gap exists

Healthcare experience analytics peers have been systematically consolidated at 7-8x revenue:

  • Medallia → Thoma Bravo $6.4B (2021, ≈11x)
  • Qualtrics → Silver Lake/CPPIB $12.5B (2023, ≈7-8x)
  • SurveyMonkey/Momentive → STG $1.5B (2023, ≈3x, outlier on deteriorating fundamentals)
  • Press Ganey Forsta → Qualtrics $6.75B (October 2025, ≈7-8x) — healthcare specialist, most relevant comp

Applied to NRC's $137M FY25 revenue: $960M-$1.2B implied enterprise value vs $400M market cap (+140-175%).

The synthesis requires connecting Schedule 13D/A exhibit language (Item 6, options-vesting hurdle) to 8-K governance changes to the October 2025 Press Ganey transaction. Small-cap ($400M), 2-3 analyst coverage, signal buried in legal drafting at exhibit level.

Risks (ranked by impact)

  1. April 28 earnings miss. If Q1 recognized revenue does not inflect above Q4 2025's $35.2M while TRCV grew, the gap is structural (churn, price/mix erosion) not mechanical timing. Reframes the governance cluster as defensive.
  2. Credit conditions tighten. LBO math for a $960M+ healthcare SaaS take-out requires cheap leverage. IG spreads widening meaningfully removes the bid.
  3. Qualtrics Press Ganey integration fails. Removes the most natural strategic acquirer for 18+ months.
  4. Activist 13D filed. Reframes governance cluster from preemption-grooming to defense. Different mechanism, different outcome distribution.
  5. Hays transition interrupted (health, unexpected events).

Catalysts

  • Apr 28, 2026 — Q1 earnings; TRCV and recognized revenue; resolves conversion test.
  • Mid-May 2026 — Q1 13F filings deadline; new holder > 5% would indicate external catalyst behind governance changes.
  • Jun 23, 2026 — Annual Meeting; declassification effective; proxy access live.
  • Dec 31, 2026 — Founder options vesting hurdle ($170M TRCV).
  • Dec 31, 2027 — 18-24 month window for strategic process announcement.

What would change our mind

  • Q1 revenue ≤ $35M or TRCV flat/declining at April 28 → thesis breaks.
  • Activist Schedule 13D filed → mechanism changes; reassess.
  • Qualtrics public commentary ruling out further M&A → key acquirer offline.
  • Investment-grade OAS widening > 75bps sustained → LBO math deteriorates.
  • Large strategic or PE 13G/13D filer appears → confirms thesis, size up.

Evidence

EvidenceSourceCredibilityLR
Peer take-privates at 7-8x revenue; Press Ganey Forsta → Qualtrics $6.75B (Oct 2025) is live healthcare-specialist compQualtrics press release 2025-10-060.902.5
TRCV $152M+ all-time high, +13% YoY, 5 consecutive sequential quarters8-K Item 7.01, 2026-04-200.902.0
Hays 13D/A Item 6: 4,833 options at $39.54 strike vest on TRCV ≥ $170M by Dec 31, 2026Schedule 13D/A Amendment No. 3, 2026-03-270.951.8
CFO Harrison open-market buy $98K at $12.27 (Form 4 code P, Feb 17); April 20 equity enhancementForm 4 2026-02-17; 8-K Item 5.02 2026-04-200.951.5
2025-26 proxy-season context: declassification + proxy access are top-5 shareholder proposals; NRC fits preemption patternHarvard Corp Gov 2026; Cleary Gottlieb 20250.851.4
Board declassification + proxy access 3% threshold + Chair formalization8-K Item 5.03, 2026-04-200.951.3
FY2025 revenue -3.9%, GAAP NI -53%, SG&A +22% YoY (bear evidence)10-K FY20250.950.85

Cumulative raw LR ≈23; correlation-adjusted ≈11-12 after grouping the grooming cluster (Schedule 13D/A, 8-K governance, rename, preemption context) as one correlated signal.

Position framing

Not a position recommendation. Forward EV probability-weighted ~+47% over 18-24 months; intrinsic fair value ≈$24-28 on that calculation. April 28 is a 7-day binary dominating near-term volatility. Sizing decision is separate from thesis decision; this memo is the thesis.

Predictions (live in worldview for calibration):

  • Q1 2026 recognized revenue ≥ $36M (2026-04-28): 55%
  • TRCV ≥ $170M by Dec 31, 2026: 70%
  • Strategic process announced by Dec 31, 2027: 45%
  • Acquired at EV ≥ $950M by Dec 31, 2027: 25%